8-K: Neurocrine Reports Strong Q3 2025 Sales Growth

Neurocrine Biosciences announced robust third-quarter 2025 financial results, driven by significant year-over-year growth in total net product sales and strong performance from INGREZZA and CRENESSITY.

Summary

• Total net product sales for the third quarter of 2025 reached $790 million, reflecting 28% year-over-year growth and 16% sequential growth over the second quarter of 2025.
• INGREZZA net product sales for the third quarter of 2025 were $687 million, representing 12% year-over-year growth and 10% sequential growth, driven by record quarterly new and total prescriptions.
• CRENESSITY net product sales for the third quarter of 2025 were $98 million, with 540 total new patient enrollment start forms and 80% reimbursement coverage for dispensed scripts.
• CRENESSITY net product sales through the first nine months of 2025 totaled $166 million, with 1,617 total new patient enrollment forms.
• Initiated a second Phase 3 registrational clinical trial for direclidine as a potential treatment for adults with schizophrenia.
• Presented new data from the Phase 2 SAVITRI study, showing statistically significant and clinically meaningful improvement in depression severity with osavampator.
• Presented new data from the Phase 4 KINECT-PRO and KINECT-HD2 studies, confirming INGREZZA's long-term safety, tolerability, and sustained improvements in tardive dyskinesia and Huntington's disease chorea.
• Appointed Mike Sibley as Senior Vice President and General Manager of the Neuropsychiatry franchise.
• Planned expansion of the INGREZZA and CRENESSITY sales teams is expected to be completed by the end of the first quarter of 2026.
• GAAP net income for the third quarter of 2025 was $209.5 million, or $2.04 per diluted share, compared to $129.8 million, or $1.24 per diluted share, for the third quarter of 2024.
• Non-GAAP net income for the third quarter of 2025 was $222.1 million, or $2.17 per diluted share, compared to $189.2 million, or $1.81 per diluted share, for the third quarter of 2024.
• Cash, cash equivalents, and marketable securities totaled approximately $2.1 billion as of September 30, 2025.
• Reaffirmed full-year 2025 INGREZZA net product sales guidance of $2,500 million to $2,550 million.
• Updated full-year 2025 GAAP R&D expense guidance to $1,000 million to $1,020 million and Non-GAAP R&D expense guidance to $910 million to $930 million.
• Updated full-year 2025 GAAP SG&A expense guidance to $1,140 million to $1,160 million and Non-GAAP SG&A expense guidance to $1,010 million to $1,030 million.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant year-over-year sales growth for its key products, INGREZZA and CRENESSITY. The pipeline is advancing well with multiple compounds in late-stage clinical trials, and full-year guidance for INGREZZA was reaffirmed. The cash position is robust, indicating financial health and capacity for continued investment.

Positives

• Total net product sales grew 28% year-over-year to $790 million in Q3 2025, demonstrating strong market demand.
• INGREZZA net product sales increased 12% year-over-year to $687 million, achieving record quarterly new and total prescriptions.
• CRENESSITY's launch is strong, generating $98 million in Q3 2025 sales with 540 new patient enrollment forms and 80% reimbursement coverage.
• GAAP net income for Q3 2025 significantly increased to $209.5 million from $129.8 million in Q3 2024.
• GAAP diluted earnings per share rose to $2.04 in Q3 2025 from $1.24 in Q3 2024.
• The company's pipeline is advancing with a second Phase 3 trial initiated for direclidine in schizophrenia and positive Phase 2 data for osavampator in major depressive disorder.
• A robust cash, cash equivalents, and marketable securities balance of approximately $2.1 billion provides strong financial flexibility.
• Full-year 2025 INGREZZA sales guidance was reaffirmed, indicating confidence in continued strong performance.
• Planned expansion of INGREZZA and CRENESSITY sales teams by Q1 2026 is expected to maximize commercial momentum.

Negatives

• Increased GAAP Research and Development (R&D) expense to $250.0 million in Q3 2025 from $195.0 million in Q3 2024, reflecting investments in an expanded portfolio.
• Increased GAAP Selling, General, and Administrative (SG&A) expense to $291.6 million in Q3 2025 from $234.3 million in Q3 2024, due to CRENESSITY launch activities and INGREZZA sales team expansion.
• Non-GAAP net income for the nine months ended September 30, 2025, decreased to $459.9 million from $482.9 million for the same period in 2024.

Risks

• Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general.
• Risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
• Risks related to the development of product candidates.
• Risks associated with dependence on third parties for development, manufacturing, and commercialization activities.
• Risks that the FDA or other regulatory authorities may make adverse decisions regarding products or product candidates.
• Risks that development activities may not be initiated or completed on time or at all, may be delayed, may not be successful, may not replicate previous clinical trial results, may fail to demonstrate safety and effectiveness, or may not be predictive of real-world results.
• Risks that the potential benefits of collaboration agreements may never be realized.
• Risks that products and/or product candidates may be precluded from commercialization by proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions, or incidents of misuse.
• Risks associated with government and third-party regulatory and/or policy efforts which may impose sales and pharmaceutical pricing controls or limit coverage and/or reimbursement.
• Risks associated with competition from other therapies or products, including potential generic entrants.

Future Outlook

Neurocrine Biosciences reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2,500 million to $2,550 million. The company updated its full-year 2025 GAAP R&D expense guidance to $1,000 million to $1,020 million and Non-GAAP R&D expense guidance to $910 million to $930 million. Full-year 2025 GAAP SG&A expense guidance was updated to $1,140 million to $1,160 million and Non-GAAP SG&A expense guidance to $1,010 million to $1,030 million. The company plans to host an R&D Day in San Diego on December 16, 2025, and expects to complete the expansion of its INGREZZA and CRENESSITY sales teams by the end of the first quarter of 2026, aiming to maximize commercial momentum and advance its robust neuroscience pipeline.

Management Comments

• "Neurocrine's third quarter commercial results highlight the meaningful impact that INGREZZA and CRENESSITY are having on patients' lives." Kyle W. Gano, Ph.D., Chief Executive Officer.
• "INGREZZA achieved another record quarter in new patient starts and total prescriptions, further demonstrating continued unmet need within the tardive dyskinesia and Huntington's chorea market." Kyle W. Gano, Ph.D., Chief Executive Officer.
• "CRENESSITY's strong launch reflects its status as a first-in-class therapy that is changing standard of care treatment for patients with classic congenital adrenal hyperplasia." Kyle W. Gano, Ph.D., Chief Executive Officer.
• "With registration-enabling clinical trials enrolling for osavampator in major depressive disorder and direclidine in schizophrenia, Neurocrine Biosciences is well positioned to lead the next wave of innovation in neuroscience, advancing transformative therapies that meaningfully improve the lives of patients." Kyle W. Gano, Ph.D., Chief Executive Officer.

Industry Context

The strong performance of INGREZZA and the successful launch of CRENESSITY demonstrate Neurocrine's ability to capture market share in specialized neuroscience indications, particularly in movement disorders and rare endocrine conditions. The advancement of its pipeline with direclidine and osavampator into late-stage clinical trials positions the company for future growth in competitive neuropsychiatric markets like major depressive disorder and schizophrenia, where there remains significant unmet medical need. The planned expansion of sales teams indicates a strategic commitment to maximizing commercial reach and penetration in a dynamic and competitive biopharmaceutical landscape.

Comparison to Industry Standards

• The 28% year-over-year total net product sales growth is robust, especially for a company with established products, indicating strong market penetration and demand compared to typical mature pharmaceutical growth rates.
• CRENESSITY's launch, with $98 million in Q3 sales and 80% reimbursement coverage, suggests a highly successful market entry for a first-in-class therapy, often exceeding initial expectations for novel treatments in rare disease markets.
• The advancement of two compounds (osavampator and direclidine) into Phase 3 trials simultaneously demonstrates a strong and active R&D pipeline, comparable to leading biopharmaceutical innovators in the neuroscience space.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased net income and EPS, robust cash position, and advancing pipeline, which could lead to increased shareholder value.
• Patients: Positive impact through continued availability and strong demand for INGREZZA and CRENESSITY, and the advancement of new potential treatments for major depressive disorder and schizophrenia.
• Employees: Positive impact through planned expansion of sales teams, indicating job growth and stability.
• Customers (Healthcare Providers): Continued access to effective treatments and new options in development.

Next Steps

• Host R&D Day in San Diego on December 16, 2025.
• Complete expansion of INGREZZA and CRENESSITY sales teams by the end of the first quarter of 2026.
• Continue enrollment in registration-enabling clinical trials for osavampator in major depressive disorder and direclidine in schizophrenia.

Key Dates

Recommendation

The company delivered exceptional Q3 2025 financial results, significantly exceeding prior year performance in net product sales, net income, and EPS. Both key commercial products, INGREZZA and CRENESSITY, demonstrated robust growth and strong market penetration, with INGREZZA achieving record patient starts and CRENESSITY showing a highly successful launch with excellent reimbursement coverage. The pipeline is actively advancing with two promising candidates in Phase 3 trials for major indications (MDD and schizophrenia), indicating strong future growth potential. The reaffirmation of INGREZZA's full-year guidance and a healthy cash position further underscore the company's operational strength and financial stability. These factors collectively suggest a strong positive trajectory for the company, making it an attractive investment.

Keywords

Neurocrine Biosciences, NBIX, Q3 2025 Earnings, Financial Results, INGREZZA, CRENESSITY, Tardive Dyskinesia, Huntington's Chorea, Congenital Adrenal Hyperplasia, Neuroscience, Biopharmaceutical, Clinical Trials, Osavampator, Direclidine, Major Depressive Disorder, Schizophrenia, Drug Development, Pharmaceutical Sales